Theratechnologies Inc

TH-T

Analysis and Opinions about TH-T

Signal
Opinion
Expert
WAIT
WAIT
October 3, 2019
Best quarter is the last one, which ends in February. December - May is optimal holding period. Lately, it's been trending lower. No reason to be enticed just yet. Want to see support at major moving averages.
Show full opinionHide full opinion
Best quarter is the last one, which ends in February. December - May is optimal holding period. Lately, it's been trending lower. No reason to be enticed just yet. Want to see support at major moving averages.
COMMENT
COMMENT
August 13, 2019
Biotechs can be very volatile. 2016 to early-2018 saw an uptrend, then turned down to the present. Be cautious now. TH-T is waiting for FDA approvals of its drugs which could swing this up sharply.
Show full opinionHide full opinion
Biotechs can be very volatile. 2016 to early-2018 saw an uptrend, then turned down to the present. Be cautious now. TH-T is waiting for FDA approvals of its drugs which could swing this up sharply.
BUY
BUY
May 24, 2019
If this was a fundamental disaster, it's going to be news driven. If it's the only company in the sector that's falling, tech analysis goes out the window. It's at a pocket after a big pullback. It's a gamble, but it's probably at a point to buy right now.
Show full opinionHide full opinion
If this was a fundamental disaster, it's going to be news driven. If it's the only company in the sector that's falling, tech analysis goes out the window. It's at a pocket after a big pullback. It's a gamble, but it's probably at a point to buy right now.
PARTIAL BUY
PARTIAL BUY
January 4, 2019
Every biotech company always has some life-altering technology, and it's always way too positive. Small-mid caps like this can have big moves. Reversing a sideways trend, and breaking up to new levels, so that's positive. Maybe some movement up to $12. Take a small position, don't expose yourself too much. Support will be around $8.50, and if it breaks, start exiting.
Show full opinionHide full opinion
Every biotech company always has some life-altering technology, and it's always way too positive. Small-mid caps like this can have big moves. Reversing a sideways trend, and breaking up to new levels, so that's positive. Maybe some movement up to $12. Take a small position, don't expose yourself too much. Support will be around $8.50, and if it breaks, start exiting.
SPECULATIVE BUY
SPECULATIVE BUY
August 28, 2018

Had a sharp run, then a sharp pullback. Technically it looks good here. You could buy it here. But he doesn't know this company well.

Show full opinionHide full opinion

Had a sharp run, then a sharp pullback. Technically it looks good here. You could buy it here. But he doesn't know this company well.

PAST TOP PICK
PAST TOP PICK
February 8, 2018

(A Top Pick July 10/17 - Down 13%.) He knew it was high risk. The biggest risk would be a non-approval or delay on the process of getting a drug approved. A delay came to place. Still watch the story for the future.

Show full opinionHide full opinion

(A Top Pick July 10/17 - Down 13%.) He knew it was high risk. The biggest risk would be a non-approval or delay on the process of getting a drug approved. A delay came to place. Still watch the story for the future.

TOP PICK
TOP PICK
July 10, 2017

They are taking the profits and cash flow from their drug to introduce a second drug, expected next year. (Analysts’ target: $9.50).

Show full opinionHide full opinion

They are taking the profits and cash flow from their drug to introduce a second drug, expected next year. (Analysts’ target: $9.50).

BUY
BUY
March 17, 2008
Canadian. Excellent phase 3 product results. A take over target, in a position of being sold right now. They have lots of cash. At this level it’s a dollar below financing. Good product. Would buy at this price.
Show full opinionHide full opinion
Canadian. Excellent phase 3 product results. A take over target, in a position of being sold right now. They have lots of cash. At this level it’s a dollar below financing. Good product. Would buy at this price.
BUY
BUY
March 17, 2008
Excellent phase 3 results. They are a takeover target, they have lots of cash. Annoyed at management because last month they had 61 million in cash, and decided to put the company up for sale, while at the same time decided to raise money. They can't have it both ways. Nothing wrong with the product. Good one to hold and to buy. Should be stable.
Show full opinionHide full opinion
Excellent phase 3 results. They are a takeover target, they have lots of cash. Annoyed at management because last month they had 61 million in cash, and decided to put the company up for sale, while at the same time decided to raise money. They can't have it both ways. Nothing wrong with the product. Good one to hold and to buy. Should be stable.
BUY
BUY
October 15, 2007
Had 2 good phase 3 trials. 2nd trial is going on right now. Long-term data was very effective. FDA approval will probably happen in the next year. Probably the best takeout candidate in a biotechnology space.
Show full opinionHide full opinion
Had 2 good phase 3 trials. 2nd trial is going on right now. Long-term data was very effective. FDA approval will probably happen in the next year. Probably the best takeout candidate in a biotechnology space.
STRONG BUY
STRONG BUY
August 17, 2007
Bought today. Have had great results on their phase 3. They've done their financing, they've got their cash. Go to market probably in 2010, 2011. Likely will be acquired. Mixed view of what the drug could be worth.
Show full opinionHide full opinion
Bought today. Have had great results on their phase 3. They've done their financing, they've got their cash. Go to market probably in 2010, 2011. Likely will be acquired. Mixed view of what the drug could be worth.
DON'T BUY
DON'T BUY
March 27, 2007
Think you are arriving at the party late on this one. He would have preferred to buy on the breakout pattern in late 2006.
Show full opinionHide full opinion
Think you are arriving at the party late on this one. He would have preferred to buy on the breakout pattern in late 2006.
BUY
BUY
February 6, 2007
Phase 3 shoed their drug did not have side effects. This resulted in a large move in the stock price. Now doing a financing, which will be a net positive for the stock. Could be a takeout or could be a partnership.
Show full opinionHide full opinion
Phase 3 shoed their drug did not have side effects. This resulted in a large move in the stock price. Now doing a financing, which will be a net positive for the stock. Could be a takeout or could be a partnership.
WEAK BUY
WEAK BUY
November 17, 2005
Management team's not bad. A very, very cheap stock. Have a good balance sheet. Thinks you can make money by buying it here regardless of what happens. Would prefer a larger market cap company.
Show full opinionHide full opinion
Management team's not bad. A very, very cheap stock. Have a good balance sheet. Thinks you can make money by buying it here regardless of what happens. Would prefer a larger market cap company.
BUY
BUY
October 28, 2003
Very bullish on this stock. Has a lot of cash. A good price.
Show full opinionHide full opinion
Very bullish on this stock. Has a lot of cash. A good price.
Showing 1 to 15 of 16 entries

Theratechnologies Inc(TH-T) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for Theratechnologies Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Theratechnologies Inc(TH-T) Frequently Asked Questions

What is Theratechnologies Inc stock symbol?

Theratechnologies Inc is a Canadian stock, trading under the symbol TH-T on the Toronto Stock Exchange (TH-CT). It is usually referred to as TSX:TH or TH-T

Is Theratechnologies Inc a buy or a sell?

In the last year, 1 stock analyst published opinions about TH-T. 1 analyst recommended to BUY the stock. 0 analyst recommended to SELL the stock. The latest stock analyst recommendation is WAIT. Read the latest stock experts' ratings for Theratechnologies Inc.

Is Theratechnologies Inc a good investment or a top pick?

Theratechnologies Inc was recommended as a Top Pick by Jon Vialoux on 2019-10-03. Read the latest stock experts ratings for Theratechnologies Inc.

Why is Theratechnologies Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Theratechnologies Inc worth watching?

1 stock analyst on Stockchase covered Theratechnologies Inc In the last year. It is a trending stock that is worth watching.

What is Theratechnologies Inc stock price?

On 2020-02-20, Theratechnologies Inc (TH-T) stock closed at a price of $3.6.